☆ 4.1 Article

Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis

Therapeutics and Clinical Risk Management (2016)

Journal

Therapeutics and Clinical Risk Management

Volume Volume 4, Issue -, Pages 337-344

Publisher

Dove Medical Press Ltd.

DOI: 10.2147/tcrm.s1209

Keywords

-

Categories

Health Care Sciences & Services

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.